November 7, 2017

After-Hours Actives: Comcast Corporation (NASDAQ:CMCSA), JPMorgan Chase & Co. (NYSE:JPM), Merck & Co., Inc. (NYSE:MRK)

Comcast Corporation (NASDAQ:CMCSA)’s stock on Tuesday traded at beginning with a price of $35.57 and when day-trade ended the stock finally edged up 2.39% to reach at $36.39. Analyst’s mean target price for CMCSA is $46.21 while analysts mean recommendation is 1.70. Stock value has moved between $30.58 – 42.31 in last one year.

Analyst’s ratings play a very important role in outlining a stock’s performance. Let us check out how analysts have ranked CMCSA based on current scenarios. Stock has got OUTPERFORM rating from 15 analyst(s) whereas last month 15 analyst(s) have given outperform rating. SELL rating has been given by 0 analyst(s) and 15 analyst(s) given BUY rating to the stock. Company fiscal year is ending in December and analysts’ consensus recommendation is Outperform for CMCSA and estimated EPS for next quarter is $ 0.48 .

Comcast Corporation (NASDAQ:CMCSA) yearly performance is 18.32% and net profit margin is 12.00%. Annual EPS Growth of past 5 years is 18.90%. The current share price indicates that stock is -13.73% away from its one year high and is moving 19.21% ahead of its 52-week low.

On 07 November 2017, JPMorgan Chase & Co. (NYSE:JPM) stock finally close at $98.75. JPM’s distance from 20 day simple moving average is -0.67% and distance from 50-Day simple moving average is 3.25%. In last 4 months performance of JPM was 5.58% while its price to sale ratio is 5.55 and price to book ratio is 1.50.

Merck & Co., Inc. (NYSE:MRK)‘s stock on Tuesday finally plummeted -0.52% to reach at $55.59. Analyst’s mean target price for MRK is $69.85 while analysts mean recommendation is 2.40. Stock value has moved between $54.5 – 66.98 in last one year.

Stock has got OUTPERFORM rating from 5 analyst(s) whereas last month 9 analyst(s) have given outperform rating. SELL rating has been given by 0 analyst(s) and 5 analyst(s) given BUY rating to the stock. Company fiscal year is ending in December and analysts’ consensus recommendation is Outperform for MRK and estimated EPS for next quarter is $ 0.94 .

Merck & Co., Inc. (NYSE:MRK) yearly performance is -7.43% and net profit margin is 10.90%. Annual EPS Growth of past 5 years is -7.00%. The current share price indicates that stock is -16.78% away from its one year high and is moving 2.17% ahead of its 52-week low.

Leave a Reply

Your email address will not be published. Required fields are marked *